Weight-Loss drug tested before prostate surgery in new pilot study
NCT ID NCT06759701
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a weight-loss drug called tirzepatide can help overweight or obese men with intermediate-risk prostate cancer lose weight before their prostate removal surgery. The study will enroll 30 participants and focus on safety and how well the program works. It is not a cure for cancer, but aims to improve surgical outcomes by reducing weight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?